Use of Recombinant Factor VIIa in Patients with Amniotic Fluid Embolism: A Systematic Review of Case Reports
Leighton, Barbara L. M.D.*; Wall, Michael H. M.D., F.C.C.M.†; Lockhart, Ellen M. M.D.‡; Phillips, Louise E. B.Sc. (Hons), M.P.H., Ph.D.§; Zatta, Amanda J. B.Sc. (Hons), Ph.D.‖
Background: Patients with amniotic fluid embolism (AFE) (major cardiac and pulmonary symptoms plus consumptive coagulopathy) have high circulating tissue factor concentrations. Recombinant factor VIIa (rVIIa) has been used to treat hemorrhage in AFE patients even though rVIIa can combine with circulating tissue factor and form intravascular clots. A systematic review was done of case reports from 2003 to 2009 of AFE patients with massive hemorrhage who were and were not treated with rVIIa to assess the thrombotic complication risk.
Methods: MEDLINE was searched for case reports of AFE patients receiving rVIIa (rVIIa cases) and of AFE patients who received surgery to control bleeding but no rVIIa (cohorts who did not receive rVIIa). Additional AFE case reports were obtained from the Food and Drug Administration, the Australian and New Zealand Haemostasis Registry, and scientific meeting abstracts. The risk of a negative outcome (permanent disability or death) in rVIIa cases versus cohorts who did not receive rVIIa was calculated using risk ratio and 95% confidence interval.
Results: Sixteen rVIIa cases and 28 cohorts were identified who did not receive rVIIa. All patients had surgery to control bleeding. Death, permanent disability, and full recovery occurred in 8, 6, and 2 rVIIa cases and 7, 4, and 17 cohorts who did not receive rVIIa (risk ratio 2.2, 95% CI 1.4–3.7 for death or permanent disability vs. full recovery).
Conclusion: Recombinant factor VIIa cases had significantly worse outcomes than cohorts who did not receive rVIIa. It is recommended that rVIIa be used in AFE patients only when the hemorrhage cannot be stopped by massive blood component replacement.
What We Already Know about This Topic
* The role of recombinant factor VIIa (rVIIa) in the treatment of amniotic fluid embolism, which can be complicated by hemorrhage, is unclear
What This Article Tells Us That Is New
* In a review of case reports of amniotic fluid embolism from 2003 to 2009, the 16 patients who received rVIIa had significantly worse outcomes (major organ thrombosis and death) compared with 28 cohorts who did not receive this therapy
CONSUMPTIVE coagulopathy and major cardiac and pulmonary symptoms are the hallmarks of the syndrome of amniotic fluid embolism (AFE).1
Because AFE is a rare condition that does not naturally occur in nonhuman animals, case reports are a major source of information about this syndrome. When caring for patients with massive postpartum hemorrhage, some anesthesiologists have administered procoagulant drugs, including recombinant factor VIIa (rVIIa) (NovoSeven®; Novo Nordisk A/S, Bagsvaerd, Denmark), aprotinin, tranexamic acid, and fibrinogen concentrate, in addition to blood components. This therapy generally works well because most postpartum hemorrhage is caused by uterine atony or birth trauma, conditions not associated with increased circulating tissue factor concentrations. However, a recent review also recommends the use of rVIIa to treat hemorrhage from intractable coagulopathy in patients with AFE, a disease that is associated with increased circulating tissue factor concentrations.2
Factor VIIa initiates the extrinsic coagulation pathway by combining with tissue factor.3
Tissue factor is normally present in very low concentrations in the bloodstream. A cut in a blood vessel exposes tissue factor to circulating factor VIIa, which starts a cascade resulting in fibrin deposition and the reestablishment of vascular integrity.3
In theory, the administration of rVIIa to patients with high circulating concentrations of tissue factor could lead to widespread inappropriate fibrin deposition in vital organs, including the brain, heart, kidneys, and liver. Circulating tissue factor concentrations are high in patients with disseminated intravascular coagulopathy (DIC), including patients with DIC caused by AFE.3
The package insert for NovoSeven® warns that “patients with DIC … have an increased risk of developing thrombotic events ….”4
To assess the risk of thrombotic complications, we systematically reviewed case reports from 2003 to 2009 of patients with massive hemorrhage attributed to AFE who were and were not treated with rVIIa.
Materials and Methods
The Washington University in Saint Louis Human Research Protection Office approved this study. We searched MEDLINE for case reports describing the use of rVIIa in patients with AFE (rVIIa cases). We retrieved rVIIa cases using the following medical subject heading terms: “amniotic fluid embolism” or “anaphylactoid syndrome of pregnancy” combined with “recombinant factor VIIa,” “VIIa,” or “NovoSeven.” After determining the time period during which these cases were reported, we researched MEDLINE using the terms “amniotic fluid embolism” or “anaphylactoid syndrome of pregnancy” for AFE cases during that time period in which surgery was used to control bleeding and in which there was no use of rVIIa (cohorts who did not receive rVIIa). Surgery is used to control postpartum hemorrhage only when the bleeding cannot be stopped by standard medical means; we added this requirement to restrict the cohorts who did not receive rVIIa to patients with massive hemorrhage. We hand-searched the abstracts of the Society for Obstetric Anesthesia and Perinatology and the American Society of Anesthesiologists from 1999 to 2009 for additional rVIIa cases and for cohorts who did not receive rVIIa. We filed a Freedom of Information Act request with the Food and Drug Administration to obtain information on adverse drug effects with rVIIa. We requested information from the Australian and New Zealand Haemostasis Registry, the Northern Europe Factor 7a in Obstetric Hemorrhage Registry, and the American Society of Anesthesiologists Closed Claims Project on rVIIa use in AFE patients.5–7
We contacted the authors of articles and abstracts for more information as needed. Non-English case reports were translated by anesthesiologists who are native speakers of the non-English languages. Demographic and clinical course details were scrutinized to avoid duplicate reporting of patients.
We considered the diagnosis of AFE confirmed if patients had at least one cardiac (hypotension or cardiac arrest) and one pulmonary (dyspnea, cyanosis, hypoxemia, or respiratory arrest) symptom in addition to DIC. This is the same definition of AFE used by the AFE registries in the United States and the United Kingdom.1
Patients were not included if the diagnosis of AFE could not be confirmed. We defined massive transfusion as the transfusion of ≥10 units of packed red blood cells (PRBC). We obtained the fresh frozen plasma (FFP):PRBC ratio by dividing the number of FFP units received by the number of PRBC units received. We classified patients as having had minor surgery if the maximum intervention for bleeding (dilation and curettage, B-Lynch suture placement, intrauterine balloon catheter placement) did not include exploratory laparotomy, hysterectomy, or uterine artery embolization or ligation.
The risk of a negative outcome (permanent disability or death) in rVIIa cases versus cohorts who did not receive rVIIa was calculated using risk ratio and 95% CI. To determine whether rVIIa cases and cohorts who did not receive rVIIa differed, we compared age (normally distributed) using independent samples Student t test, the number of PRBC units and the FFP:PRBC ratio (not normally distributed) using the Mann–Whitney U test, and surgery type (minor vs. not) and transfusion requirement (massive transfusion vs. not) using Fisher exact test. P < 0.05 was considered significant. SAS version 9.2 (SAS Institute, Cary, NC) was used for analyses.
Our first MEDLINE search yielded five rVIIa cases.9–13
One rVIIa case received both rVIIa and aprotinin.13
Two patients mentioned in several review articles as having had successful outcomes after receiving rVIIa for AFE did not have AFE according to the strict diagnostic criteria we used and are not included in this review.14
Three additional rVIIa cases were described in Society for Obstetric Anesthesia and Perinatology abstracts.16–18
Four rVIIa cases were obtained from the Food and Drug Administration (unpublished data, Food and Drug Administration file #2009–4281, October 13, 2009); however, one of the Food and Drug Administration rVIIa cases also was described in a published case report.10
Five rVIIa cases were obtained from the Australian and New Zealand Haemostasis Registry.19
No additional rVIIa cases were obtained from the Northern Europe Factor 7a in Obstetric Hemorrhage Registry or the American Society of Anesthesiologists Closed Claims Project. Surgery to control bleeding was performed in all 16 rVIIa cases: hysterectomy (n = 7), hysterectomy plus a subsequent exploratory laparotomy (n = 2), hysterectomy plus right salpingo-oophrectomy (n = 1), exploratory laparotomy (n = 3), exploratory laparotomy plus additional surgery (n = 2), and intrauterine balloon catheter insertion (n = 1) (table 1
). All case reports for retrieved rVIIa cases were published, presented, or registered in English or German between May 1, 2003 and May 3, 2009.
Our second MEDLINE search identified 181 articles discussing AFE or anaphylactoid syndrome of pregnancy between 2003 and 2009. These articles contained details of 78 patients identified by the authors as having AFE. Five patients, described previously, met our definition of AFE and received rVIIa. Forty-seven patients either did not meet our definition of AFE (n = 35) or did not have surgery to control bleeding (n = 12). Twenty-six patients (cohorts who did not receive rVIIa) met our definition of AFE, underwent a surgical procedure to control bleeding, and did not receive rVIIa.20–43
Five of these patients received fibrinogen concentrate,20
two patients received tranexamic acid,26
two patients received aprotinin,27
and one patient received prothrombin complex concentrate.41
Information on two additional cohorts who did not receive rVIIa was available in Society for Obstetric Anesthesia and Perinatology abstracts.44
The surgical procedures in these 28 control subjects were hysterectomy (n = 12), hysterectomy plus a subsequent exploratory laparotomy (n = 2), uterine artery embolization or ligation (n = 5), exploratory laparotomy (n = 5), B-Lynch suture placement during cesarean delivery (n = 1), and dilation and curettage (n = 3) (table 2
). Case reports on all retrieved cohorts who did not receive rVIIa were published or presented in English or French between August 11, 2003 and September 7, 2009.
All of the patients in both groups had an intense DIC and bled profusely from the uterus, the bladder, the mouth, the incision, and venipuncture sites. All patients received pressors to treat hypotension or cardiac arrest, although it is not possible from the case reports to determine a complete list of the pressors used or the doses administered. Heroic efforts were used to obtain sufficient blood products to treat one patient; the US Navy diverted two ships for blood donation during unscheduled port visits for a cohort who did not receive rVIIa: the 20-yr-old wife of a Navy sailor.38
Approximately 88% (14 of 16) of rVIIa cases had a negative outcome (permanent disability or death) compared with 39% (11 of 28) of cohorts who did not receive rVIIa (risk ratio 2.2, 95% CI 1.4–3.7) (table 3
). Among those who lived, 75% (6 of 8) of rVIIa cases had permanent disability (coma, stroke × 2, memory loss, pulmonary hypertension, new systemic hypertension) compared with 19% (4 of 21) of cohorts who did not receive rVIIa (left-sided motor weakness, short term memory loss × 2, panhypopituitarism) (risk ratio 4.0, 95% CI 1.5–10.4).
Recombinant factor VIIa cases and cohorts who did not receive rVIIa did not differ significantly by age (rVIIa cases: mean 35.0 yr, 95% CI 31.4–38.5; cohorts who did not receive rVIIa: mean 32.9 yr, 95% CI 30.7–35.0; P = 0.27), whether or not the surgery was minor (rVIIa cases 1 of 16 (6%), cohorts who did not receive rVIIa 4 of 28 (14%), P = 0.64), whether or not the patient received a massive transfusion (rVIIa cases 13 of 14 (93%), cohorts who did not receive rVIIa 15 of 22 (68%), P = 0.12), the number of PRBC units transfused (rVIIa cases: median 16, minimum 3, maximum 66; cohorts who did not receive rVIIa: median 11.5, minimum 2, maximum 80; P = 0.22), or the FFP:PRBC ratio (rVIIa cases: median 0.67, minimum 0.13, maximum 4.33; cohorts who did not receive rVIIa: median 0.91,minimum 0.30, maximum 3.00; P = 0.14).
Patients with a negative outcome (permanent disability or death) versus full recovery did not differ significantly by age (negative outcome mean 34.3 yr, 95% CI 31.6–37.0; full recovery mean 32.7 yr, 95% CI 30.3–35.2; P = 0.40), whether the surgery was minor (negative outcome 1/25 (4%), full recovery 4 of 19 (21%), P = 0.15), whether they received a massive transfusion (negative outcome 16 of 19 (84%), full recovery 12 of 17 (71%), P = 0.43), the number of PRBC units transfused (negative outcome median 16, minimum 3, maximum 80; full recovery median 13, minimum 2, maximum 54; P = 0.23) or the FFP:PRBC ratio (negative outcome median 0.74, minimum 0.13, maximum 4.33; full recovery median 0.92, minimum 0.30, maximum 3.00; P = 0.25).
Thrombosis in major organs is the most serious complication of rVIIa administration. Our review suggests that clinically significant thrombosis is associated with rVIIa treatment in AFE patients with DIC. Patients who received rVIIa had significantly worse outcomes than cohorts who did not receive rVIIa. (risk ratio 2.2, 95% CI 1.4–3.7).
The medical management of coagulopathy-induced hemorrhage is an unresolved clinical problem. rVIIa, which activates the extrinsic coagulation pathway by combining with circulating tissue factor, is the drug most likely to trigger inappropriate fibrin deposition.3
Thrombosis also can occur with tranexamic acid or aprotinin, which inhibit fibrinolysis.46
Among the five patients in this review treated with aprotinin and/or tranexamic acid, multiple organ failure and death occurred in two patients: one who also received rVIIa and one who did not.13
Anticoagulation might prevent the initiation of consumptive coagulopathy but is also likely to worsen an already massive hemorrhage. An agent that may prove useful in the future is fibrinogen concentrate, which recently became commercially available in the United States. Four of the five patients treated with fibrinogen concentrate, all cohorts who did not receive rVIIa from Europe, made full recoveries, whereas the fifth patient, who was also treated with tranexemic acid, died.20
Recombinant factor VIIa has been used successfully to treat postpartum hemorrhage in patients who do not have high circulating tissue factor concentrations, such as those with uterine atony, uterine rupture, and abnormal placentation.6
Patients with preeclampsia or preterm prelabor rupture of membranes have moderately high circulating tissue factor concentrations; however, patients with the HELLP variant of preeclampsia (Hemolysis, Elevated Liver enzymes, and Low Platelet count) have been treated successfully with rVIIa.19
Coagulopathy can be both the cause of massive hemorrhage in AFE and the result of insufficient coagulation factor replacement during massive transfusion.51
Trauma patients who have had massive tranfusion frequently develop an acute coagulopathy because of tissue trauma, shock, hemodilution, hypothermia, acidemia, and inflammation. Studies in trauma patients have shown that replacement of PRBC, FFP, and platelets in a ratio of 1:1:1 usually provides adequate concentrations of all clotting factors and fibrinogen. However, if fibrinogen is less than 1 g/l, cryoprecipitate or fibrinogen concentrate should be given.51
Correcting the coagulopathy and stopping the hemorrhage as soon as possible are important to avoid the potentially lethal complications of acidosis and hypothermia.
Amniotic fluid, the amniochorion, and the placenta are rich sources of both procoagulant and anticoagulant factors. Surfactant, a lipoprotein produced by fetal lungs and present in increasing amounts in amniotic fluid with increasing gestational age, is structurally similar to tissue thromboplastin and possesses significant thromboplastic activity.53
There is a close correlation between amniotic fluid surfactant concentration and the ability of amniotic fluid to shorten plasma recalcification time (r = 0.77).53
Amniotic fluid and the amniochorion contain a cysteine protease that directly activates factor X.55
Cells in amniotic fluid externalize phosphatidylserine, which promotes the activation of factor X and prothrombin.56
Amniotic fluid cells also externalize tissue factor, the most potent naturally occurring procoagulant.56
Amniotic fluid irreversibly aggregates platelets.54
The term placenta contains high concentrations of anticoagulants, including tissue factor pathway inhibitor-2 (a strong inhibitor of activated factor X), thrombomodulin, and annexin V.57
Many of these factors are essential for the maintenance of pregnancy. Transgenic mice with low tissue factor concentrations have a 42% incidence of fatal midgestational maternal hemorrhage.57
Thrombomodulin knockout mice resorb all embryonic tissue in midgestation.57
Maternal and fetal survival require sequestration and local application of powerful procoagulant and anticoagulant factors; loss of the coagulation balance or the sequestration can be fatal.
The mortality rates we observed in rVIIa cases (50%) and cohorts who did not receive rVIIa (25%) are consistent with other reports of AFE mortality. The United Kingdom Amniotic Fluid Embolism Register reported a mortality rate of 29.5% from 1997 to 2004.8
A population-based study in the United States from 1998 to 2003 found a case fatality rate of 21.6%.58
Previous reports found mortality rates of 40–80%.1
Although AFE is a rare disease, it is currently the second leading cause of direct maternal death in the United States.59
Because this is a retrospective study, we cannot determine whether rVIIa caused or was merely associated with poor patient outcome. However, the low incidence of AFE (7.7 per 100,000 births in the United States) makes a prospective, randomized trial of AFE therapy impossible.58
The patients in this review were described in case reports, presented at conferences, or entered into registries of complications. Although none of the demographic differences between rVIIa cases and cohorts who did not receive rVIIa were significant, rVIIa patients were 2.1 yr older, had a slightly lower FFP:PRBC ratio (0.67 vs.
0.91), and were slightly more likely to have major surgery (94% vs.
86%) and have massive transfusion (93% vs.
68%). Sicker patients, including patients in whom DIC could not be controlled with blood component therapy, may have been selected to receive rVIIa. It is possible that the rVIIa patients may have required more pressor support than the cohorts who did not receive rVIIa. There may have been underreporting of patients with successful results or of maternal deaths in either the rVIIa patients or the cohorts who did not receive rVIIa. We used rigid criteria for the diagnosis of AFE and systematic search criteria to minimize these potential sources of error.
In conclusion, the use of rVIIa to treat postpartum hemorrhage in patients with severe consumptive coagulopathy and AFE was associated with worse outcome compared with cohorts who did not receive rVIIa. Most of the survivors treated with rVIIa suffered permanent damage that could have been caused by organ thrombosis. We recommend that the initial therapy of AFE-associated consumptive coagulopathy should consist of blood component replacement, including PRBC, FFP, platelets, cryoprecipitate, and possibly fibrinogen concentrate. We recommend that rVIIa be used in AFE patients only when the hemorrhage cannot be stopped by massive blood component replacement.
1. Clark SL, Hankins GD, Dudley DA, Dildy GA, Porter TF: Amniotic fluid embolism: Analysis of the national registry. Am J Obstet Gynecol 1995; 172:1158–69
2. Conde-Agudelo A, Romero R: Amniotic fluid embolism: An evidence-based review. Am J Obstet Gynecol 2009; 201:445.e1–13
3. Østerud B, Bjørklid E: The tissue factor pathway in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27:605–17
4. NovoSeven® [package insert]. Bagsvaerd Denmark: Novo Nordisk A/S; 2010
5. Davies JM, Posner KL, Lee LA, Cheney FW, Domino KB: Liability associated with obstetric anesthesia: A closed claims analysis. ANESTHESIOLOGY 2009; 110:131–9
6. Isbister J, Phillips L, Dunkley S, Jankelowitz G, McNeil J, Cameron P: Recombinant activated factor VII in critical bleeding: Experience from the Australian and New Zealand Haemostasis Register. Intern Med J 2008; 38:156–65
7. Alfirevic Z, Elbourne D, Pavord S, Bolte A, Van Geijn H, Mercier F, Ahonen J, Bremme K, Bødker B, Magnúsdóttir EM, Salvesen K, Prendiville W, Truesdale A, Clemens F, Piercy D, Gyte G: Use of recombinant activated factor VII in primary postpartum hemorrhage: The Northern European registry 2000–2004. Obstet Gynecol 2007; 110:1270–8
8. Tuffnell DJ: United kingdom amniotic fluid embolism register. BJOG 2005; 112:1625–9
9. Mato J: Suspected amniotic fluid embolism following amniotomy: A case report. AANA J 2008; 76:53–9
10. Nagarsheth NP, Pinney S, Bassily-Marcus A, Anyanwu A, Friedman L, Beilin Y: Successful placement of a right ventricular assist device for treatment of a presumed amniotic fluid embolism. Anesth Analg 2008; 107:962–4
11. Chanimov M, Ben-Shlomo I, Chayen B, Gurovich V, Friedland M, Cohen ML, Bahar M: Amniotic fluid embolism: A plea for better brain protection. Isr Med Assoc J 2008; 10:154–5
12. Kahyaoglu I, Kahyaoglu S, Mollamahmutoglu L: Factor VIIa treatment of DIC as a clinical manifestation of amniotic fluid embolism in a patient with fetal demise. Arch Gynecol Obstet 2009; 280:127–9
13. Kretzschmar M, Zahm DM, Remmler K, Pfeiffer L, Victor L, Schirmeister W: Pathophysiological and therapeutic aspects of amniotic fluid embolism (anaphylactoid syndrome of pregnancy): Case report with lethal outcome and overview. Anaesthesist 2003; 52:419–26
14. Lim Y, Loo CC, Chia V, Fun W: Recombinant factor VIIa after amniotic fluid embolism and disseminated intravascular coagulopathy. Int J Gynaecol Obstet 2004; 87:178–9
15. Prosper SC, Goudge CS, Lupo VR: Recombinant factor VIIa to successfully manage disseminated intravascular coagulation from amniotic fluid embolism. Obstet Gynecol 2007; 109:524–5
16. Nyirenda T, Huffnagle H, Huffnagle S, Grodecki W, Elia E: Amniotic fluid embolus? A case presentation (A-195). Presented at: Annual Meeting of the Society for Obstetric Anesthesia and Perinatology, Banff, Alberta, Canada, May 17, 2007
17. Bastin CE, Shih G: An abnormal presentation of amniotic fluid embolism (A-75). Presented at: Annual Meeting of the Society for Obstetric Anesthesia and Perinatology, Washington, District of Columbia, May 1, 2009
18. Harter S, Riley E: Profound hemorrhage in a parturient with placenta previa and percreta complicated by amniotic fluid embolism and disseminated intravascular coagulation (A-192). Presented at: Annual Meeting of the Society for Obstetric Anesthesia and Perinatology, Washington, District of Columbia, May 2, 2009
19. Phillips LE, McLintock C, Pollock W, Gatt S, Popham P, Jankelowitz G, Ogle R, Cameron PA, Australian and New Zealand Haemostasis Registry: Recombinant activated factor VII in obstetric hemorrhage: Experiences from the Australian and New Zealand Haemostasis Registry. Anesth Analg 2009; 109:1908–15
20. Biron-Andréani C, Morau E, Schved JF, Hédon B, Dechaud H: Amniotic fluid embolism with haemostasis complications: Primary fibrinogenolysis or disseminated intravascular coagulation? Pathophysiol Haemost Thromb 2003; 33:170–1
21. Goldszmidt E, Davies S: Two cases of hemorrhage secondary to amniotic fluid embolus managed with uterine artery embolization. Can J Anesth 2003; 50:917–21
22. Porat S, Leibowitz D, Milwidsky A, Valsky DV, Yagel S, Anteby EY: Transient intracardiac thrombi in amniotic fluid embolism. Br J Obstet Gynaecol 2004; 111:506–10
23. Cragun JM, Ellestad SC, Panni MK: Amniotic fluid embolism presenting after uterine manipulation under general anesthesia: A case with a positive outcome. Resuscitation 2008; 77:145–6
24. Manchanda R, Sriemevan A: Anaphylactoid syndrome caused by amniotic fluid embolism following manual removal of placenta. J Obstet Gynaecol 2005; 25:201–2
25. McDonnell NJ, Chan BO, Frengley RW: Rapid reversal of critical haemodynamic compromise with nitric oxide in a parturient with amniotic fluid embolism. Int J Obstet Anesth 2007; 16:269–73
26. Nagar MP, Gratrix AP, O'Beirne HA, Enright SM: Survival following amniotic fluid embolism and cardiac arrest complicated by sub-capsular liver haematoma. Int J Obstet Anesth 2005; 14:62–5
27. Stehr SN, Liebich I, Kamin G, Koch T, Litz RJ: Closing the gap between decision and delivery: Amniotic fluid embolism with severe cardiopulmonary and haemostatic complications with a good outcome. Resuscitation 2007; 74:377–81
28. Rault S, Pirrello O, Langer B, Nisand I: Amniotic fluid embolism: Two case reports. Gynecol Obstet Fertil 2006; 34:127–30
29. Stroup J, Haraway D, Beal JM: Aprotinin in the management of coagulopathy associated with amniotic fluid embolus. Pharmacotherapy 2006; 26:689–93
30. Peitsidou A, Peitsidis P, Tsekoura V, Spathi A, Tzaneti A, Samanta E, Siampalioti G, Kioses E: Amniotic fluid embolism managed with success during labour: Report of a severe clinical case and review of literature. Arch Gynecol Obstet 2008; 277:271–5
31. Fekhkhar K, Rachet B, Gillet R, Provost D, Lalo JP, Rieu M, Compere V, Roussel F, Marpeau L, Dureuil B: Amniotic fluid embolism during curettage for a pregnancy arrest: Case report. Ann Fr Anesth Reanim 2009; 28:795–8
32. Robillard J, Gauvin F, Molinaro G, Leduc L, Adam A, Rivard GE: The syndrome of amniotic fluid embolism: A potential contribution of bradykinin. Am J Obstet Gynecol 2005; 193:1508–12
33. Meletti JF, de Miranda RV: Amniotic fluid embolism during vaginal delivery under analgesia. Case report. Rev Bras Anestesiol 2008; 58:397–402
34. Kendrick JE 4th, Leath CA 3rd, Melton SM, Straughn JM Jr: Use of a fascial prosthesis for management of abdominal compartment syndrome secondary to obstetric hemorrhage. Obstet Gynecol 2006;107:493–6
35. Verrost N, Zegdi R, Ciobotaru V, Tsatsaris V, Goffinet F, Fabiani JN, Mignon A: Ventricular fibrillation during termination of pregnancy. Lancet 2007; 369:1900
36. Ho CH, Chen KB, Liu SK, Liu YF, Cheng HC, Wu RSC: Early application of extracorporeal membrane oxygenation in a patient with amniotic fluid embolism. Acta Anaesthesiol Taiwan 2009; 49:99–102
37. Matsuo K, Lynch MA, Kopelman JN, Atlas RO: Anaphylactoid syndrome of pregnancy immediately after intrauterine pressure catheter placement. Am J Obstet Gynecol 2008; 198:e8–9
38. De Jong MJ, Fausett MB: Anaphylactoid syndrome of pregnancy: A devastating complication requiring intensive care. Crit Care Nurse 2003; 23:42–8
39. Doumouchtsis SK, Papageorghiou AT, Vernier C, Arulkumaran S: Management of postpartum hemorrhage by uterine balloon tamponade: Prospective evaluation of effectiveness. Acta Obstet Gynecol Scand 2008; 87:849–55
40. Mahshid N, Ahmad S, Nahid M, Afshin F: Sudden cardiac arrest during cesarean section – a possible case of amniotic fluid embolism. Middle East J Anesthesiol 2009; 20:315–7
41. Annecke T, Geisenberger T, Kürzl R, Penning R, Heindl B: Algorithm-based coagulation management of catastrophic amniotic fluid embolism. Blood Coagul Fibrinolysis 2010; 21:95–100
42. Mathelier AC, Karachorlu K: Placenta previa and accreta complicated by amniotic fluid embolism. Int J Fertil Womens Med 2006; 51:28–32
43. James CF, Feinglass NG, Menke DM, Grinton SF, Papadimos TJ: Massive amniotic fluid embolism: Diagnosis aided by emergency transesophageal echocardiography. Int J Obstet Anesth 2004; 13:279–83
44. Serebnitsky S, Ciliberto C: Amniotic fluid embolism: Case report of classical presentation with atypical outcome (A-235). Presented at: Annual Meeting of the Society for Obstetric Anesthesia and Perinatology, Chicago, Illinois, May 4, 2008
45. Tyagaraj KC: Amniotic fluid embolism in a post-cesarean section patient: A rare, delayed presentation (A-160). Presented at: Annual Meeting of the Society for Obstetric Anesthesia and Perinatology, Banff, Alberta, Canada, May 19, 2007
46. Asakura H, Sano Y, Yamazaki M, Morishita E, Miyamoto K, Nakao S: Role of fibrinolysis in tissue-factor-induced disseminated intravascular coagulation in rats: An effect of tranexamic acid. Haematologica 2004; 89:757–8
47. Ahonen J, Jokela R, Korttila K: An open non-randomized study of recombinant activated factor VII in major postpartum haemorrhage. Acta Anaesthesiol Scand 2007; 51:929–36
48. Baudo F, Caimi TM, Mostarda G, de Cataldo F, Morra E: Critical bleeding in pregnancy: A novel therapeutic approach to bleeding. Minerva Anestesiol 2006; 72:389–93
49. Abdel Gader AM, Al-Mishari AA, Awadalla SA, Buyuomi NM, Khashoggi T, Al-Hakeem M: Total and free tissue factor pathway inhibitor in pregnancy hypertension. Int J Gynaecol Obstet 2006; 95:248–53
50. Erez O, Espinoza J, Chaiworapongsa T, Gotsch F, Kusanovic JP, Than NG, Mazaki-Tovi S, Vaisbuch E, Papp Z, Yoon BH, Han YM, Hoppensteadt D, Fareed J, Hassan SS, Romero R: A link between a hemostatic disorder and preterm PROM: A role for tissue factor and tissue factor pathway inhibitor. J Matern Fetal Neonatal Med 2008; 21:732–44
51. Sihler KC, Napolitano LM: Massive transfusion: New insights. Chest 2009; 136:1654–67
52. Borgman MA, Spinella PC, Perkins JG, Grathwohl KW, Repine T, Beekley AC, Sebesta J, Jenkins D, Wade CE, Holcomb JB: The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 2007; 63:805–13
53. Higuchi M, Hirano H, Maki M: The thromboplastic activity of lung surfactant in amniotic fluid and its application to prenatal assessment of fetal lung maturity. Tohoku J Exp Med 1981; 133:267–73
54. Salem HH, Walters WA, Perkin JL, Handley CJ, Firkin BG: Aggregation of human platelets by amniotic fluid. Br J Obstet Gynaecol 1982; 89:733–7
55. Gordon SG, Hasiba U, Cross BA, Poole MA, Falanga A: Cysteine proteinase procoagulant from amnion-chorion. Blood 1985; 66:1261–5
56. Zhou J, Liu S, Ma M, Hou J, Yu H, Lu C, Gilbert GE, Shi J: Procoagulant activity and phosphatidylserine of amniotic fluid cells. Thromb Haemost 2009; 101:845–51
57. Lanir N, Aharon A, Brenner B: Procoagulant and anticoagulant mechanisms in human placenta. Semin Thromb Hemost 2003; 29:175–84
58. Abenhaim HA, Azoulay L, Kramer MS, Leduc L: Incidence and risk factors of amniotic fluid embolisms: A population-based study on 3 million births in the United States. Am J Obstet Gynecol 2008; 199:49.e1–8
59. Clark SL, Belfort MA, Didly GA, Herbst MA, Meyers JA, Hankins GD: Maternal death in the 21st
century: Causes, prevention, and relationship to cesarean delivery. Am J Obstet Gynecol 2008; 199:36.e1–5
This article has been cited 2 time(s).
Annales Francaises D Anesthesie Et De ReanimationAmniotic fluid embolism: An updateAnnales Francaises D Anesthesie Et De Reanimation
Pathogenesis and management of peripartum coagulopathic calamities (disseminated intravascular coagulation and amniotic fluid embolism)
Thrombosis Research, 131():
© 2011 American Society of Anesthesiologists, Inc.
Publication of an advertisement in Anesthesiology Online does not constitute endorsement by the American Society of Anesthesiologists, Inc. or Lippincott Williams & Wilkins, Inc. of the product or service being advertised.